Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax with Cladribine, Cytarabine, and Azacitidine in Newly Diagnosed Monocytic and Mutated AML
NCT06504459Phase 2Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jan 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), acute monocytic leukemia (AML-M5), sponsored by OHSU Knight Cancer Institute. Started Jan 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)acute monocytic leukemia (AML-M5)
Beyond the preview
Go deeper on NCT06504459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504459.